Aim: To evaluate the base-line serum sICAM-1 levels among patients with GO and levels sICAM-1 at the end of 6 month follow up after different schemes of GO treatment.
Material and methods: 72 patients with GO have been surveyed. Patients have been put into 4 groups depending on spent treatment: 1st group 26 patients received methylprednisolone per os 1 mg/kg in a combination with plasmapheresis; 2nd group 14 patients received pulse-therapy by methylprednisolone; 3rd group 18 patients received methylprednisolone per os 1 mg/kg in a combination with plasmapheresis and autogemomagnitotherapy; 4th group 14 patients received methylprednisolone per os 1 mg/kg.
We used «Human sICAM ELISA, BMS 201» kits for measured serum sICAM-1 levels.
Results: Serum levels sICAM-1 were 48.13±12.61 in the control group.
|1st group||2nd group||3rd group||4th group|
|Baseline serum sICAM-1 (M±σ, ng/ml)||81.82±33.3b||93.03±33.32b||79.04±21.94b||90.34±29.53b|
|sICAM-1 (M±σ, ng/ml) after 6 month follow up after GO treatment course||56.16±10.99a, c||50.82±13.77c||55.02±12.89a, c||64.27±29.87a, c|
|Δ sICAM-1 (Me)||17.55d||41.16||20.32d||23.07d|
|aP<0.05, b P<0.00001 vs control group; cP<0.05 vs same groups before GO treatment; dP<0.05 vs 2nd group).|
Conclusions: The base-line serum sICAM-1 levels was significantly higher in all groups vs control and sICAM-1 levels significantly decreased in all groups at the end of 6 months follow up after the complete course of GO treatment. The treatment of GO with used pulse-therapy by methylprednisolone was better among different schemes of Graves ophthalmopathy treatment, taking into account that ΔsICAM-1 was significantly higher in this group.